Its a pretty bloody good pipeline.
Havent had a chance yet to look at how that chemo drug works on its own. A potential licence deal here would be non dilutive finance right?
All data here helps support the mode of action of the NK drug, which helps with itd future pipeline use.
Should be an interesting week. Hopefully another announcement or two before Friday.
This market cap in no way represents the pipeline. Friday could become a positive pivot point if they can sort the money.
- Forums
- ASX - By Stock
- Ann: AML patient achieves Complete Response in CHM CORE-NK trial
CHM
chimeric therapeutics limited
Add to My Watchlist
0.00%
!
0.4¢

Its a pretty bloody good pipeline. Havent had a chance yet to...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M |
Open | High | Low | Value | Volume |
0.4¢ | 0.4¢ | 0.4¢ | $69.39K | 17.34M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
40 | 26298938 | 0.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.4¢ | 9474957 | 10 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
40 | 26298938 | 0.003 |
16 | 13800507 | 0.002 |
10 | 50600000 | 0.001 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.004 | 9474957 | 10 |
0.005 | 14691167 | 22 |
0.006 | 13747410 | 16 |
0.007 | 4700000 | 4 |
0.008 | 8542434 | 6 |
Last trade - 11.21am 18/06/2025 (20 minute delay) ? |
Featured News
CHM (ASX) Chart |
The Watchlist
MEM
MEMPHASYS LIMITED.
Professor John Aitken, Scientific Director
Professor John Aitken
Scientific Director
Previous Video
Next Video
SPONSORED BY The Market Online